BioSpace News Archive

Iridex Corporation today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse ® Transscleral Laser Therapy (TLT) using Iridex’ Cyclo G6 ® Laser and the MicroPulse P3 ® Delivery Device.

Genome & Company (KOSDAQ: 314130), a clinical stage biotech leading in microbiome therapeutic development announced on January 18th (local time) that a poster was presented on the positive topline results from the phase 2 clinical trial (NCT05419362) in gastric cancer of its microbiome immunotherapy, GEN-001 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2024).

Babson Diagnostics today announced its new, highly automated microsample laboratory has been awarded accreditation by the College of American Pathologists (CAP) based on the results of a recent on-site inspection.

UroGen Pharma Ltd. today announced the submission of the Chemistry, Manufacturing, and Controls (CMC) section of the New Drug Application (NDA) for UGN-102 (mitomycin) for intravesical solution to the U.S. Food and Drug Administration (FDA).

ZWI Therapeutics, Inc. announces a Series A financing, the appointment of pharmaceutical industry veterans Drs. Larry Miller and Ron Cohen as Independent Directors to the company’s Board of Directors.

Twist Bioscience Corporation today announced the expansion of Twist Express Genes, a new leading gene synthesis service with an order to shipping turnaround starting at five business days 1, to include larger DNA preparations up to 1 milligram.

Optikos is excited to announce the release of their ColliMeter™ measurement system for the precise setup and qualification of collimators.

Ferring Pharmaceuticals announced today it is presenting the methodology for the ADSTILADRIN in BLadder cancEr (ABLE-41) Real World Evidence (RWE) study at the 20th Annual American Society of Clinical Oncologists Genitourinary Cancers Symposium (ASCO GU).

Biofidelity and Fidelis Sustainability Distribution (Fidelis) today announced that they have entered into an agreement to make ASPYRE®-Lung available to VA Medical Centers and active military institutions across the US.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”) announces an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs).